Compare · ALZN vs AVXL

ALZN vs AVXL

Side-by-side comparison of Alzamend Neuro Inc. (ALZN) and Anavex Life Sciences Corp. (AVXL): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. ALZN focuses on Biotechnology: Pharmaceutical Preparations, while AVXL focuses on Biotechnology: Biological Products (No Diagnostic Substances).
  • AVXL is the larger of the two at $86.2M, about 14.4x ALZN ($6.0M).
  • AVXL has been more active in the news (7 items in the past 4 weeks vs 1 for ALZN).
  • AVXL has more recent analyst coverage (6 ratings vs 1 for ALZN).
MetricALZNAVXL
Company
Alzamend Neuro Inc.
Anavex Life Sciences Corp.
Price
-
-
Market cap
$6.0M
$86.2M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2021
News (4w)
1
7
Recent ratings
1
6
ALZN

Alzamend Neuro Inc.

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

AVXL

Anavex Life Sciences Corp.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.

Latest ALZN

Latest AVXL